Aytu BioPharma logo
Aytu BioPharma
AYTU | NASDAQ
Chart Builder DCF Calculator
$1.82
+$0.04 (+2.25%)
At close: Nov 16, 2026, 4:00 PM ET
$2.62
+$0.80 (+43.97%)
After-hours: Nov 16, 2026, 7:59 PM ET

Aytu BioPharma Company Profile

Company profile explained

Company Profile

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Key Executives

Name Position
Joshua R. Disbrow Chief Executive Officer & Director
Ryan J. Selhorn Chief Financial Officer, Corporate Secretary & Treasurer
Gerwin Westfield Senior Vice President of Scientific Affairs
Greg Pyszczymuka Chief Commercial Officer
Jarrett T. Disbrow Chief Business Officer
Margaret Cabano Vice President of Operations

Latest SEC Filings

Date Type Title
Oct 27, 2026 DEFA14A Filing
Oct 22, 2026 DEF 14A Filing
Sep 22, 2026 10-K Annual Report
Sep 22, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
View All SEC Filings ➞
Aytu BioPharma
Aytu BioPharma logo
Country United States
IPO Date Sep 25, 2008
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 76
CEO Joshua R. Disbrow

Contact Details

7900 East Union Avenue, Suite 920 Denver, Colorado 80237 United States

Stock Details

Ticker Symbol AYTU
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001385818
CUSIP Number 054754858
ISIN Number US0547548588
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.